Literature DB >> 29860246

ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.

Peter Valent1,2.   

Abstract

Various myeloid neoplasms, including the myelodysplastic syndromes (MDS), bear a certain risk of progression to secondary acute myeloid leukemia (sAML). The evolution from low-risk to high-risk MDS and finally to sAML suggests that leukemogenesis is a multistep process. However, even before an overt neoplasm, such as an MDS, develops, "prediagnostic" clonal conditions may be identified. With the advent of large-scale genomic screens, such conditions may be detected quite frequently and early in apparently healthy individuals. Recent data suggest that these conditions increase with age and are indeed associated with an increased risk of the occurrence of MDS or another myeloid neoplasm. In other patients, unexplained cytopenia may be detected and may precede MDS. More recently, diagnostic criteria for potential pre-MDS conditions, including idiopathic cytopenia of uncertain significance and clonal hematopoiesis with indeterminate potential, have been proposed. The current article provides an overview of pre-MDS states and related criteria through which these conditions can be discriminated from each other and from MDS. In addition, the clinical implications and management of pre-MDS states are discussed.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Clonal cytopenia of unknown significance; Clonal hematopoiesis with indeterminate potential; Diagnostic criteria; Idiopathic cytopenia of uncertain significance; Idiopathic dysplasia of unknown significance; Myeloid neoplasms

Mesh:

Year:  2018        PMID: 29860246      PMCID: PMC7115849          DOI: 10.1159/000489042

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  46 in total

1.  Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients.

Authors:  T Schroeder; L Ruf; A Bernhardt; B Hildebrandt; M Aivado; C Aul; N Gattermann; R Haas; U Germing
Journal:  Ann Oncol       Date:  2010-05-03       Impact factor: 32.976

Review 2.  Morphology, cytogenetics and classification of MDS.

Authors:  Aristoteles Giagounidis; Detlef Haase
Journal:  Best Pract Res Clin Haematol       Date:  2013-10-01       Impact factor: 3.020

3.  Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome.

Authors:  L Malcovati; M G Della Porta; M Lunghi; C Pascutto; L Vanelli; E Travaglino; M Maffioli; P Bernasconi; M Lazzarino; R Invernizzi; M Cazzola
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

Review 4.  Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

5.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Authors:  Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

6.  Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.

Authors:  Judith Neukirchen; Michael Lauseker; Barbara Hildebrandt; Ann-Christin Nolting; Jennifer Kaivers; Guido Kobbe; Norbert Gattermann; Rainer Haas; Ulrich Germing
Journal:  Cancer       Date:  2017-07-26       Impact factor: 6.860

Review 7.  The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes.

Authors:  David P Steensma
Journal:  Best Pract Res Clin Haematol       Date:  2017-09-22       Impact factor: 3.020

8.  Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Authors:  Peter Valent; Attilio Orazi; David P Steensma; Benjamin L Ebert; Detlef Haase; Luca Malcovati; Arjan A van de Loosdrecht; Torsten Haferlach; Theresia M Westers; Denise A Wells; Aristoteles Giagounidis; Michael Loken; Alberto Orfao; Michael Lübbert; Arnold Ganser; Wolf-Karsten Hofmann; Kiyoyuki Ogata; Julie Schanz; Marie C Béné; Gregor Hoermann; Wolfgang R Sperr; Karl Sotlar; Peter Bettelheim; Reinhard Stauder; Michael Pfeilstöcker; Hans-Peter Horny; Ulrich Germing; Peter Greenberg; John M Bennett
Journal:  Oncotarget       Date:  2017-07-05

Review 9.  Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Christoph Bock; Tracy I George; Stephen J Galli; Jason Gotlib; Torsten Haferlach; Gregor Hoermann; Olivier Hermine; Ulrich Jäger; Lukas Kenner; Hans Kreipe; Ravindra Majeti; Dean D Metcalfe; Alberto Orfao; Andreas Reiter; Wolfgang R Sperr; Philipp B Staber; Karl Sotlar; Charles Schiffer; Giulio Superti-Furga; Hans-Peter Horny
Journal:  EBioMedicine       Date:  2017-11-26       Impact factor: 8.143

10.  Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults.

Authors:  Andrew L Young; Grant A Challen; Brenda M Birmann; Todd E Druley
Journal:  Nat Commun       Date:  2016-08-22       Impact factor: 14.919

View more
  15 in total

1.  Impact of HFE gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes.

Authors:  Mathias Schneeweiss-Gleixner; Georg Greiner; Susanne Herndlhofer; Julia Schellnegger; Maria-Theresa Krauth; Karoline V Gleixner; Friedrich Wimazal; Corinna Steinhauser; Michael Kundi; Renate Thalhammer; Ilse Schwarzinger; Gregor Hoermann; Harald Esterbauer; Manuela Födinger; Peter Valent; Wolfgang R Sperr
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

Review 2.  [Differential diagnosis of reactive cytopenias].

Authors:  Thomas Menter; Stefan Dirnhofer; Alexandar Tzankov
Journal:  Pathologie (Heidelb)       Date:  2022-05-19

Review 3.  Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology.

Authors:  Gregor Hoermann; Georg Greiner; Andrea Griesmacher; Peter Valent
Journal:  J Pers Med       Date:  2020-08-20

4.  The diagnostic and prognostic role of flow cytometry in idiopathic and clonal cytopenia of undetermined significance (ICUS/CCUS): A single-center analysis of 79 patients.

Authors:  Konstantinos Dimopoulos; Olga Kristina Hansen; Lene Dissing Sjö; Leonie Saft; Ida Marianne Schjødt; Jakob Werner Hansen; Kirsten Grønbaek
Journal:  Cytometry B Clin Cytom       Date:  2019-09-03       Impact factor: 3.058

Review 5.  Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML.

Authors:  Peter Valent; Wolfgang Kern; Gregor Hoermann; Jelena D Milosevic Feenstra; Karl Sotlar; Michael Pfeilstöcker; Ulrich Germing; Wolfgang R Sperr; Andreas Reiter; Dominik Wolf; Michel Arock; Torsten Haferlach; Hans-Peter Horny
Journal:  Int J Mol Sci       Date:  2019-02-12       Impact factor: 5.923

6.  Antibodies specific to ferritin light chain polypeptide are frequently detected in patients with immune‑related pancytopenia.

Authors:  Shanfeng Hao; Yang Zhang; Luogang Hua; Ning Xie; Na Xiao; Huaquan Wang; Rong Fu; Zonghong Shao
Journal:  Mol Med Rep       Date:  2020-06-26       Impact factor: 2.952

7.  Clinical relevance of clonal hematopoiesis in persons aged ≥80 years.

Authors:  Marianna Rossi; Manja Meggendorfer; Matteo Zampini; Mauro Tettamanti; Emma Riva; Erica Travaglino; Matteo Bersanelli; Sara Mandelli; Alessia Antonella Galbussera; Ettore Mosca; Elena Saba; Chiara Chiereghin; Nicla Manes; Chiara Milanesi; Marta Ubezio; Lucio Morabito; Clelia Peano; Giulia Soldà; Rosanna Asselta; Stefano Duga; Carlo Selmi; Maria De Santis; Karolina Malik; Giulia Maggioni; Marilena Bicchieri; Alessia Campagna; Cristina A Tentori; Antonio Russo; Efrem Civilini; Paola Allavena; Rocco Piazza; Giovanni Corrao; Claudia Sala; Alberto Termanini; Laura Giordano; Paolo Detoma; Aurelio Malabaila; Luca Sala; Stefano Rosso; Roberto Zanetti; Claudia Saitta; Elena Riva; Gianluigi Condorelli; Francesco Passamonti; Armando Santoro; Francesc Sole; Uwe Platzbecker; Pierre Fenaux; Niccolò Bolli; Gastone Castellani; Wolfgang Kern; George S Vassiliou; Torsten Haferlach; Ugo Lucca; Matteo G Della Porta
Journal:  Blood       Date:  2021-11-25       Impact factor: 22.113

8.  Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS.

Authors:  Christina Rautenberg; Ulrich Germing; Sabrina Pechtel; Marius Lamers; Carolin Fischermanns; Paul Jäger; Stefanie Geyh; Rainer Haas; Guido Kobbe; Thomas Schroeder
Journal:  Blood Cancer J       Date:  2019-11-12       Impact factor: 11.037

9.  Immune thrombocytopenia in myeloid and lymphoid clonal disorders: an intriguing association.

Authors:  Francesco Rodeghiero
Journal:  Haematologica       Date:  2021-05-01       Impact factor: 9.941

10.  The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records.

Authors:  Tine Bichel Lauritsen; Jan Maxwell Nørgaard; Kirsten Grønbæk; Anders Pommer Vallentin; Syed Azhar Ahmad; Louise Hur Hannig; Marianne Tang Severinsen; Kasper Adelborg; Lene Sofie Granfeldt Østgård
Journal:  Clin Epidemiol       Date:  2021-06-14       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.